2012 annual shareholder meeting presentation
Post on 05-Dec-2014
1.664 Views
Preview:
DESCRIPTION
TRANSCRIPT
Cytori Therapeutics, Inc.
Annual Shareholder Meeting
August 16, 2012
9:00 AM PT
Safe Harbor Statement
This presentation may contain certain ‘forward-looking statements’. All
statements, other than statements of historical fact, that address activities, events
or developments that we intend, expect, project, believe or anticipate will or
may occur in the future are forward-looking statements. Such statements are
based upon certain assumptions and assessments made by our management in
light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be
appropriate.
The forward-looking statements included in this presentation are also subject to a
number of material risks and uncertainties. We caution investors not to place
undue reliance on the forward-looking statements contained in this presentation.
We would advise reading our annual report filed with the United States Securities
and Exchange Commission on Form 10-K for a more detailed description of these
risks.
Our Company Mission
To improve the quality and length of life
by providing innovative cell therapy products
CYTORI - The Leader in Cell Therapy
Lesley’s Story
Pre-Treatment Adjunct to Burn Resurfacing
Pre-Treatment
Lesley’s Story
Pre-Treatment
3 Weeks Post Treatment 8 Weeks Post Treatment 20 Weeks Post Treatment
Lesley’s Story
Pre-Treatment Burn Scar Repair
Pre-Treatment
18 Months
Lesley’s Story
Pre-Treatment Burn Scar Repair
Pre-Treatment
Before
18 Months
Lesley’s Story
Pre-Treatment 12 Month Post Op 18 Month Post Op
Easy to Access Cells
A small amount of fat is removed (about half a can of coke)
Point-of-Care
Your tissue is processed right at the side of your bed
About an hour …
And available when you need it
The Power of Cell Therapy
> 5,000 patients have been treated
using their own cells with Cytori products
Clinical Leadership
11%
53%
27%
1%
1% 2%
5%
> 5,000 Patients Treated (est.)
Breast Recon
Breast Augmentation
Other Fat Grafting
Cardiac
Urology
5 Clinical Trials • 3 Complete (2 CV, 1 Breast)
• 2 Ongoing (2 CV)
• Others planned
40+ Investigator Studies
>5,000 patients treated
Available in 47 countries
>8,600 patients treated
Available in 52 countries
Available globally
Cytori Product Families
Momentum is Building
Expanded soft tissue claims Recurring revenues increasing Preparing for vascular market Demand for cell & tissue banking is increasing
Preclinical Research Phase I/II Pivotal Full Market Access Private Pay/ Reimbursement
Breast /Buttock Face Augmentation
Breast Cancer Reconstruction
Soft Tissue Facial Wasting
Diabetic Foot Ulcers
Fistula
Burns
Radiation Induced Injury
SUI
Sports Related Injury
Heart Failure / No Option Chronic Myocardial Ischemia
Acute Myocardial Infarction
Critical Limb Ischemia
Puregraft
Banking
Advance Pipeline toward Market Access
Refractory Heart Failure
Emerson Perin, MD Texas Heart Institute
ATHENA TRIAL • FDA Approved Multicenter Trial • Double Blind, Placebo controlled • 45 Patients: 30 ADRC, 15 Placebo • 6 Leading US Cardiac Cell Therapy Centers
Dr. Perin, Dr. Willerson, Texas Heart Dr. Henry, Minneapolis Heart Dr. Miller, University South Florida Dr. Pepine, University of Florida, Gainsville Dr. Mendelsohn, Cardiology PC, Alabama Dr. Schatz, Scripps La Jolla, California
Acute Heart Attack
Eric Duckers, MD, PhD Rotterdam, The Netherlands
ADVANCE TRIAL • European Pivotal Trial • Prospective • Randomized (2:1) • Double Blind • Placebo controlled • Up to 216 patients for STEMI • Enrollment to begin in Q4 ’12
• G5 • The Netherlands • Canada • Poland
Intellectual Property
• 51 Patents + 2 Allowances
• 75+ Applications in process
• ~50% growth in portfolio
• Avg 1 patent / month
Shareholder Value
• Advance pipeline toward Market Access
• Manage to cash flow positive Grow revenue Control costs
• Strengthen balance sheet
Milestones Achieved in 2012
FDA approval to initiate ATHENA
CE Mark for wounds, burns, radiation, ischemia
Additional country approvals (Russia, Croatia)
Breast Reconstruction Reimbursement filing - UK
Publish 6 & 18 month data: APOLLO
Publish 12 month data: RESTORE 2
Puregraft 850 FDA & CE Mark, PG250 approvals
Grow IP Portfolio > 15%
Milestones
• Establish Strategic Partnership
• Initiate ATHENA Trial – US (First patient enrolled)
• Cardiovascular CE Mark expansion
• Additional country approvals
(Canada, Australia, New Zealand, Japan)
• FDA Appeal Resolution
• Publish 18 month data – PRECISE Trial
• Revenue growth target of $9 million
Vision
Cells concentrated from
a person’s own fat tissue, will be used to treat
a broad array of diseases in patients around the world
MISSION: To improve the quality and length of life
by providing innovative cell therapy products
Cytori is…
Defining the market for point-of-care cell therapy Delivering on the promise in cell therapy Leading in delivering cell therapy to doctors & patients
MISSION: To improve the quality and length of life
by providing innovative cell therapy products
Thank You !
Cytori: Restoring Lives
top related